CA2863178C - Immunogenic composition - Google Patents
Immunogenic composition Download PDFInfo
- Publication number
- CA2863178C CA2863178C CA2863178A CA2863178A CA2863178C CA 2863178 C CA2863178 C CA 2863178C CA 2863178 A CA2863178 A CA 2863178A CA 2863178 A CA2863178 A CA 2863178A CA 2863178 C CA2863178 C CA 2863178C
- Authority
- CA
- Canada
- Prior art keywords
- meningitidis
- carrier protein
- polysaccharide
- saccharide
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN281MU2012 | 2012-01-30 | ||
| IN281/MUM/2012 | 2012-01-30 | ||
| PCT/IB2013/050739 WO2013114268A1 (en) | 2012-01-30 | 2013-01-29 | Immunogenic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2863178A1 CA2863178A1 (en) | 2013-08-08 |
| CA2863178C true CA2863178C (en) | 2021-04-06 |
Family
ID=54259032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2863178A Active CA2863178C (en) | 2012-01-30 | 2013-01-29 | Immunogenic composition |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9198977B2 (https=) |
| EP (1) | EP2809349B1 (https=) |
| JP (1) | JP6042455B2 (https=) |
| KR (1) | KR101897317B1 (https=) |
| CN (1) | CN104302315B (https=) |
| BR (1) | BR112014018815B1 (https=) |
| CA (1) | CA2863178C (https=) |
| DK (1) | DK2809349T3 (https=) |
| ES (1) | ES2707294T3 (https=) |
| HU (1) | HUE040914T4 (https=) |
| MX (1) | MX354103B (https=) |
| PT (1) | PT2809349T (https=) |
| RU (1) | RU2634405C2 (https=) |
| SG (1) | SG11201404447WA (https=) |
| SI (1) | SI2809349T1 (https=) |
| TR (1) | TR201900778T4 (https=) |
| WO (1) | WO2013114268A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| RU2627156C2 (ru) * | 2012-11-21 | 2017-08-03 | Серум Инститьют Оф Индия Прайват Лтд. | Высокоэффективный способ получения бактериального полисахарида, получение конъюгата на его основе и иммуногенная композиция |
| EP3035957B1 (en) | 2013-08-24 | 2019-11-20 | Bharat Biotech International Limited | A bacterial vaccine and methods for manufacture thereof |
| EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
| PE20180460A1 (es) | 2015-06-08 | 2018-03-06 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos |
| WO2017006349A1 (en) * | 2015-07-04 | 2017-01-12 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
| KR102428253B1 (ko) * | 2016-03-15 | 2022-08-02 | 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 | 신규한 다당류-단백질 접합체 및 이의 제조방법 |
| CN106110316A (zh) * | 2016-06-27 | 2016-11-16 | 北京智飞绿竹生物制药有限公司 | 一种肺炎球菌结合物组合疫苗的制备方法 |
| KR102906912B1 (ko) * | 2016-09-02 | 2026-01-05 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| CN106397537B (zh) * | 2016-10-13 | 2020-01-07 | 李红臣 | 一种高效快速的多糖蛋白结合疫苗纯化分析方法 |
| JP7319929B2 (ja) * | 2017-05-05 | 2023-08-02 | セラム インスティテュート オブ インディア プライベート リミティド | 細菌性莢膜多糖ベース調製物からの不純物の除去方法 |
| JP2020525495A (ja) * | 2017-06-27 | 2020-08-27 | エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． | 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤 |
| WO2019145981A1 (en) * | 2018-01-29 | 2019-08-01 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
| WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| EP4034157A1 (en) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| CN118078981A (zh) * | 2024-04-26 | 2024-05-28 | 成都康华生物制品股份有限公司 | 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| HU227893B1 (en) * | 2000-06-29 | 2012-05-29 | Glaxosmithkline Biolog Sa | Vaccine compositions |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| CN103357002A (zh) * | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US8398983B2 (en) * | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| NZ598367A (en) * | 2005-09-01 | 2013-10-25 | Novartis Vaccines & Diagnostic | Multiple vaccination including serogroup C meningococcus |
| PL1973564T3 (pl) * | 2005-12-22 | 2017-04-28 | Glaxosmithkline Biologicals S.A. | Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| MX2012006961A (es) * | 2009-12-17 | 2012-10-03 | Fina Biosolutions Llc | Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas. |
| WO2013174832A1 (en) * | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
-
2013
- 2013-01-29 DK DK13743463.5T patent/DK2809349T3/da active
- 2013-01-29 WO PCT/IB2013/050739 patent/WO2013114268A1/en not_active Ceased
- 2013-01-29 MX MX2014009250A patent/MX354103B/es active IP Right Grant
- 2013-01-29 PT PT13743463T patent/PT2809349T/pt unknown
- 2013-01-29 RU RU2014134288A patent/RU2634405C2/ru active
- 2013-01-29 CN CN201380017781.9A patent/CN104302315B/zh active Active
- 2013-01-29 TR TR2019/00778T patent/TR201900778T4/tr unknown
- 2013-01-29 ES ES13743463T patent/ES2707294T3/es active Active
- 2013-01-29 US US14/375,385 patent/US9198977B2/en active Active
- 2013-01-29 EP EP13743463.5A patent/EP2809349B1/en active Active
- 2013-01-29 HU HUE13743463A patent/HUE040914T4/hu unknown
- 2013-01-29 CA CA2863178A patent/CA2863178C/en active Active
- 2013-01-29 BR BR112014018815-7A patent/BR112014018815B1/pt active IP Right Grant
- 2013-01-29 SG SG11201404447WA patent/SG11201404447WA/en unknown
- 2013-01-29 SI SI201331329T patent/SI2809349T1/sl unknown
- 2013-01-29 KR KR1020147024348A patent/KR101897317B1/ko active Active
- 2013-01-29 JP JP2014555364A patent/JP6042455B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX354103B (es) | 2018-02-13 |
| KR20140123553A (ko) | 2014-10-22 |
| SG11201404447WA (en) | 2014-08-28 |
| EP2809349B1 (en) | 2018-12-19 |
| US9198977B2 (en) | 2015-12-01 |
| CN104302315B (zh) | 2018-02-06 |
| PT2809349T (pt) | 2019-02-01 |
| CA2863178A1 (en) | 2013-08-08 |
| HUE040914T4 (hu) | 2019-05-28 |
| EP2809349A1 (en) | 2014-12-10 |
| SI2809349T1 (sl) | 2019-03-29 |
| JP2015509111A (ja) | 2015-03-26 |
| BR112014018815A2 (https=) | 2017-06-20 |
| BR112014018815A8 (pt) | 2017-07-11 |
| WO2013114268A1 (en) | 2013-08-08 |
| RU2634405C2 (ru) | 2017-10-26 |
| JP6042455B2 (ja) | 2016-12-14 |
| US20140377302A1 (en) | 2014-12-25 |
| DK2809349T3 (da) | 2019-02-18 |
| KR101897317B1 (ko) | 2018-09-11 |
| RU2014134288A (ru) | 2016-03-20 |
| EP2809349A4 (en) | 2015-08-26 |
| TR201900778T4 (tr) | 2019-02-21 |
| BR112014018815B1 (pt) | 2022-07-12 |
| ES2707294T3 (es) | 2019-04-03 |
| MX2014009250A (es) | 2015-03-19 |
| CN104302315A (zh) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2863178C (en) | Immunogenic composition | |
| JP7494276B2 (ja) | 非天然アミノ酸とのポリペプチド抗原接合体 | |
| US8753649B2 (en) | Polysaccharide-protein conjugate vaccines | |
| EP2366403B1 (en) | Polysaccharide-protein conjugate vaccines | |
| KR20160005793A (ko) | 담체 단백질에 대한 박테리아 다당류의 컨쥬게이션 방법 | |
| EP1664319B1 (en) | Process for producing a capsular polysaccharide for use in conjugate vaccines | |
| WO2019070994A1 (en) | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE | |
| US12053515B2 (en) | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F | |
| JP2013504588A (ja) | 免疫原性の高いタンパク質マトリックスワクチン | |
| WO2017011338A1 (en) | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use | |
| JP7851988B2 (ja) | 非天然アミノ酸とのポリペプチド抗原接合体 | |
| Moingeon | Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases | |
| EA044044B1 (ru) | Иммуногенные композиции, содержащие конъюгаты полипептид-антиген с неприродными аминокислотами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180124 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250106 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250106 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250106 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |